LAGIPRA peptide is a long-acting agonist of GIP1R. It improves insulin sensitivity by enhancing glucose handling and reduces circulating branched-chain amino acids (BCAA) and keto acids. LAGIPRA peptide holds potential for research in type 2 diabetes.
Target:
IGF-1R
* VAT and and shipping costs not included. Errors and price changes excepted
